Primary Outcome Measures:
- Expression of TUBB3 and BRCA1 in MPM tumor tissue by immunohistochemistry and RT-PCR. [ Time Frame: 2 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Association of expression of TUBB3 and BRCA1 with clinical outcome (response, survival) . [ Time Frame: 2 months ] [ Designated as safety issue: No ]
Eligibility Criteria
- Study Population
- Malignant pleural mesothelioma patients treated with vinorelbine as a second or later line chemotherapy with at least an objective response evaluation.
- Inclusion Criteria:
-
- MPM patients treated with vinorelbine in the ≥ second line setting will be retrospectively analyzed
- Patients will be selected based on the availability of tumor tissue
- Exclusion Criteria:
- NA
